Pyxis Oncology to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Kroger (NYSE: KR) announced a legal leadership succession: George Vincent will join as secretary and general counsel effective August 4, 2025, and current EVP and general counsel Christine Wheatley will retire on September 1, 2025. Vincent joins from Dinsmore & Shohl, where he served as managing partner and oversaw more than 750 lawyers across 35 states. Wheatley has been with Kroger since 2008 and served as general counsel and secretary since 2014. The announcement frames the change as a planned succession with thanks for Wheatley’s service and continuity built through a named successor and clear effective dates.

Positive

• Clear succession timetable with August 4 and September 1, 2025 effective dates
• Experienced hire: Vincent oversaw 750 lawyers in 35 states
• Continuity maintained by naming successor before Wheatley’s retirement

Negative

• Loss of in-house counsel with Wheatley serving since 2014
• Transition risk as an external hire integrates into Kroger legal operations

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will participate in the following upcoming investor conferences in November 2025:

• Guggenheim 2^nd Annual Healthcare Innovation Conference, Boston, MA, Monday, November 10, 2:30 p.m. ET. – Fireside chat.
  
  
• Stifel 2025 Healthcare Conference, New York, NY, Tuesday, November 11, 4:00 p.m. ET. – Fireside chat.
  
  

Live webcasts and replays of the Guggenheim and Stifel fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com.

About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company’s lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody drug conjugate (ADC) that targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM). EDB+FN is selectively overexpressed in the tumor microenvironment of a wide range of solid tumors and largely absent from normal adult tissues. MICVO is designed to treat solid tumors through a three-pronged mechanism of action: direct tumor cell killing, bystander effect and immunogenic cell death. MICVO is currently being evaluated in Phase 1 clinical studies in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and other solid tumors, both as monotherapy and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). Pyxis Oncology is focused on advancing MICVO, with the goal of improving outcomes for patients living with R/M HNSCC and contributing to meaningful progress in cancer treatment.

To learn more, visit www.pyxisoncology.com or follow us on LinkedIn.

Pyxis Oncology Contact
Alex Kane
IR@pyxisoncology.com

Media
Cailyn McCutcheon
Real Chemistry
cmccutcheon@realchemistry.com

FAQ

Who will be Kroger's new general counsel and when does George Vincent start (KR)?

George Vincent will join as secretary and general counsel effective August 4, 2025.

When will EVP and general counsel Christine Wheatley retire from Kroger (KR)?

Christine Wheatley has announced retirement effective September 1, 2025.

What is George Vincent's background before joining Kroger (KR)?

Vincent was a partner and former managing partner at Dinsmore & Shohl and oversaw 750 lawyers licensed in 35 states.

How long did Christine Wheatley serve as Kroger's general counsel before retirement (KR)?

Wheatley served as general counsel and secretary since 2014 and joined Kroger in 2008.

Does Kroger describe the leadership change as a planned succession (KR)?

Yes; the company framed the announcement as a planned succession and thanked Wheatley for her service.